Bempegaldesleukin联合纳武利尤单抗一线治疗转移性尿路上皮癌:PIVOT-02研究结果
PIVOT-02是一项开放标签、多队列2期研究,纳入41例既往未治疗的局部晚期/不可手术或转移性尿路上皮癌患者,接受BEMPEG 0.006 mg/kg联合纳武利尤单抗360 mg静脉每3周一次。可评估患者客观缓解率为35%(13/37),完全缓解率19%(7/37),中位无进展生存期4.1个月,中位总生存期23.7个月。
要点
- BEMPEG联合纳武利尤单抗一线治疗局部晚期/转移性尿路上皮癌客观缓解率35%(13/37),完全缓解率19%(7/37)。
- 中位无进展生存期4.1个月(95%CI 2.1-8.7),中位总生存期23.7个月(95%CI 15.8-未达到)。
- 40/41例(98%)发生至少1例治疗相关不良事件,3/4级治疗相关不良事件11例(27%),最常见为发热(4.9%;2例)。
核心结论
- BEMPEG联合纳武利尤单抗作为局部晚期/转移性尿路上皮癌一线治疗耐受性良好,并显示出抗肿瘤活性。
研究设计与样本
- 开放标签、多队列1/2期研究(PIVOT-02),纳入41例既往未治疗的局部晚期/不可手术或转移性尿路上皮癌患者。
- 患者接受BEMPEG 0.006 mg/kg联合纳武利尤单抗360 mg静脉给药,每3周一次。
- 主要目标为安全性和可评估患者的客观缓解率,次要目标为总生存期和无进展生存期。
主要发现
- 客观缓解率为35%(13/37例可评估患者),完全缓解率为19%(7/37例),中位缓解持续时间未达到。
- 中位无进展生存期为4.1个月(95%CI 2.1-8.7),中位总生存期为23.7个月(95%CI 15.8-未达到)。
- 40/41例(98%)发生至少1例治疗相关不良事件,3/4级治疗相关不良事件发生在11例(27%),最常见为发热(4.9%;2例)。
- 探索性生物标志物分析显示生物标志物与缓解之间无关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 样本量小。
- 单臂设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite recent changes in the treatment landscape, there remains an unmet need for effective, tolerable, chemotherapy-free treatments for patients with advanced/metastatic urothelial carcinoma (mUC), especially cisplatin-ineligible patients. OBJECTIVE: To evaluate the immunostimulatory interleukin-2 cytokine prodrug bempegaldesleukin (BEMPEG) plus nivolumab in patients with advanced/mUC from the phase 2 multicenter PIVOT-02 study. DESIGN, SETTING, AND PARTICIPANTS: This open-label, multicohort phase 1/2 study enrolled patients with previously untreated locally advanced/surgically unresectable or mUC (N = 41). INTERVENTION: Patients received BEMPEG 0.006 mg/kg plus nivolumab 360 mg intravenously every 3 wk. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary objectives were safety and the objective response rate (ORR) in patients with measurable disease at baseline and at least one postbaseline tumor response assessment (response-evaluable). Secondary objectives were overall survival (OS) and progression-free survival (PFS). Exploratory biomarker analyses via univariate logistic regression were performed to test the association between potential biomarkers (CD8+ tumor-infiltrating lymphocytes, tumor mutational burden, and IFN-γ gene expression profile) and response. RESULTS AND LIMITATIONS: The ORR was 35% (13/37 evaluable patients) and the complete response rate was 19% (7/37 patients); the median duration of response was not reached. Median PFS was 4.1 mo (95% confidence interval [CI] 2.1-8.7) and median OS was 23.7 mo (95% CI 15.8-not reached). Overall, 40/41 patients (98%) experienced at least one treatment-related adverse event (TRAE); grade 3/4 TRAEs occurred in 11 patients (27%), most commonly pyrexia (4.9%; 2 patients). Exploratory biomarker analyses showed no association between biomarkers and response. Limitations include the small sample size and single-arm design. CONCLUSIONS: BEMPEG plus nivolumab was well tolerated and showed antitumor activity as first-line treatment in patients with locally advanced/mUC. PATIENT SUMMARY: We investigated an immune-stimulating prodrug called bempegaldesleukin plus the antibody nivolumab as the first therapy for patients with advanced or metastatic cancer of the urinary tract. This combination had manageable treatment-related side effects and was effective in a subset of patients. This trial is registered at ClinicalTrials.gov as NCT02983045.
引用
- Siefker-Radtke AO, Cho DC, Diab A, et al. Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02. Eur Urol. 2022. PMID: 35643589. doi:10.1016/j.eururo.2022.05.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。